Q32 Bio Inc QTTB
News
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
